6976-07-4

Basic information

• Product Name: Guanidine,N-(4-methylphenyl)-, hydrochloride (1:1)
• Synonyms: Guanidine,(4-methylphenyl)-, monohydrochloride (9CI)
• CAS NO: 6976-07-4
• Molecular Formula: C₈H₁₁N₃*ClH
• Molecular Weight: 149.193
• Mol File: 6976-07-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 314.6°C at 760 mmHg
• Flash Point: 144.1°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 0.000461mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: Guanidine,N-(4-methylphenyl)-, hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: Guanidine,N-(4-methylphenyl)-, hydrochloride (1:1)(6976-07-4)
• EPA Substance Registry System: Guanidine,N-(4-methylphenyl)-, hydrochloride (1:1)(6976-07-4)

Safety Data

• Hazardous Substances Data: 6976-07-4(Hazardous Substances Data)

Usage

General Description

Guanidine, N-(4-methylphenyl)-, hydrochloride (1:1) is a chemical compound that is commonly used in pharmaceutical research and development. It is an organic compound that is composed of guanidine and 4-methylphenyl groups, with a hydrochloride salt added for stability and efficacy. Guanidine,N-(4-methylphenyl)-, hydrochloride (1:1) is known for its potential involvement in the treatment of various medical conditions such as hypertension, cardiovascular diseases, and diabetes. As a hydrochloride salt, it is more stable and soluble in water, making it easier to formulate into medications for oral and intravenous administration. Overall, Guanidine, N-(4-methylphenyl)-, hydrochloride (1:1) is a versatile chemical that has promising applications in the field of medicinal chemistry.

InChI:InChI=1/C8H11N3/c1-6-2-4-7(5-3-6)11-8(9)10/h2-5H,1H3,(H4,9,10,11)

Upstream product

• 1029802-07-0 1-[2,3-di(tert-butoxycarbonyl)guanidino]-4-methylbenzene 

Relevant articles and documents

GUANIDINE BASED COMPOUNDS

The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel guanidine and 2-aminoimidazoline compounds which are ligands of the alpha2-adrenoceptor (α2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of α2-ARs associated disorders, such as depression, schizophrenia, glaucoma and analgesia.